Forbes 2018 pharmaceutical enterprise potential list is published! 18 home screen

[China Pharmaceutical network industry trends] on June 8, Forbes China released the "2018 list of potential enterprises of listed companies" and "2018 list of potential enterprises of non listed companies" According to incomplete statistics, there are 18 enterprises in the pharmaceutical industry, including 14 listed companies and 4 non listed companies Specifically, the listed companies include Wandong Medical, innovative medical, Yongan pharmaceutical, Kelite, Dirui medical, top nine biology, saisheng pharmaceutical, Fuxiang shares, Jianfan biology, Kaikai medical, atomic high tech, Chetou pharmaceutical, Yifan biotechnology, and Jinshui biotechnology Non listed companies include feiyinuo Technology (Suzhou), Hunan Tairui medical technology, Nanjing nuowenzan biotechnology, and Shanghai Jingyi technology From the perspective of the main business of the above companies, most of them are medical machinery technology, equipment, services, APIs, raw materials and other products Among them, the specific conditions of the listed enterprises that are mainly engaged in pharmaceutical products are as follows: Yong'an pharmaceutical, with a global vision and pattern, has established a health industry chain with taurine series products as the core, leading the field of taurine functional nutrition in China The raw materials of its products come from the United States, Germany, France, Japan, Peru, New Zealand, India, Belgium, Taiwan, China and other countries and regions, ensuring the raw materials and traceability Jiuqiang biology Jiuqiang biology is a national high-tech enterprise mainly engaged in the R & D, production and sales of in vitro diagnostic products It has a series of in vitro diagnostic products that are developed synchronously with the international market Through more than ten years of rapid development, top nine biology has grown into a manufacturer of in vitro diagnostic products, and gradually occupies a place in the international IVD market Saisheng pharmaceutical is a profitable professional pharmaceutical company with a large number of businesses in China, and its product portfolio spans major therapeutic drug markets such as cancer, infectious diseases and cardiovascular diseases Looking at the products that have the potential to take the leading position in the future market and promote the long-term development of the company, the company has successfully obtained the authorization and commercialization of these products, and some other products are also in the later stage of development in China Fuxiang Pharmaceutical Co., Ltd is a pharmaceutical enterprise specializing in the research and development, production, sales and service of chemical drugs With core technology, the company is an important production base of β - lactamase inhibitor APIs in the industry, and also one of the main suppliers of carbapenems Jianfan biotechnology is a leading enterprise in the field of blood purification in China, specializing in the research, development, production and sales of biological materials and medical equipment The company has passed the ISO international quality management system certification, and has undertaken one "National 863 key project", two "national key new product projects" and three "Torch Plan projects" The product technology has reached the international advanced level The main products "DNA immune adsorption column" and "resin blood perfusion device" have a high market share Chetou pharmaceutical is a national high-tech enterprise It mainly produces nucleoside antiviral, antiphlogistic, antipyretic, analgesic, cardiovascular and other series of APIs and intermediates, naproxen (sodium), acyclovir APIs Yifan biotech Yifan biotech is an enterprise mainly engaged in biological drugs At present, the policy is favorable, the follow-up of national medical insurance, the investment of bio medicine R & D resources and funds, and the continuous progress of technology, and the outbreak of bio similar drugs as the innovative drug market in generic drugs in China is imminent.